Literature DB >> 11055620

Are schizophrenia or antipsychotic drugs a risk factor for cataracts?

A Ruigómez1, L A García Rodríguez, V J Dev, F Arellano, J Raniwala.   

Abstract

Lens changes and ocular disturbances have been reported in conjunction with the use of antipsychotic drugs. We estimated the incidence rate of a clinical diagnosis of cataract in patients with a psychotic disorder, schizophrenia, and compared it with the rate in the general population. Among the schizophrenic patients, we also examined the role of dose and duration of antipsychotic drugs on the risk of cataract development. We followed up two cohorts of patients 30-85 years of age who were included in the United Kingdom General Practice Research Database. Patients in one group had a diagnosis of schizophrenia (N = 4,209). The other group was an age- and sex-matched cohort of 10,000 patients sampled from the source population. The incidence of cataracts was 4.5 per 1,000 person-years among the general population and 3.5 in the schizophrenia population. Overall, antipsychotic drug use was not associated with the occurrence of cataracts. Nevertheless, among long-term users of chlorpromazine at daily doses of 300 mg or greater, and among users of prochlorperazine, the relative risks were 8.8 (95% confidence interval = 3.1-25.1) and 4.0 (95% confidence interval = 0.8-20.7), respectively. There is no indication that schizophrenia per se is associated with an increased risk of developing cataracts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055620     DOI: 10.1097/00001648-200011000-00002

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  8 in total

1.  A population based case-control study of cataract and inhaled corticosteroids.

Authors:  L Smeeth; M Boulis; R Hubbard; A E Fletcher
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

2.  Side effects of atypical antipsychotics: a brief overview.

Authors:  Alp Uçok; Wolfgang Gaebel
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

3.  Methotrimeprazine-induced corneal deposits and cataract revealed by urine drug profiling test.

Authors:  Seong Taeck Kim; Jae Woong Koh; Joon Mo Kim; Won Young Kim; Gwang Ju Choi
Journal:  J Korean Med Sci       Date:  2010-10-26       Impact factor: 2.153

4.  Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions.

Authors:  Dieter Schoepf; Hardeep Uppal; Rahul Potluri; Reinhard Heun
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-08-13       Impact factor: 5.270

5.  Visual impairment in persons with psychotic disorder.

Authors:  Satu Viertiö; Arja Laitinen; Jonna Perälä; Samuli I Saarni; Seppo Koskinen; Jouko Lönnqvist; Jaana Suvisaari
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-09-10       Impact factor: 4.328

Review 6.  The Contribution of Fluoride to the Pathogenesis of Eye Diseases: Molecular Mechanisms and Implications for Public Health.

Authors:  Declan Timothy Waugh
Journal:  Int J Environ Res Public Health       Date:  2019-03-08       Impact factor: 3.390

7.  Validation of the diagnosis of autism in general practitioner records.

Authors:  Eric Fombonne; Lisa Heavey; Liam Smeeth; Laura C Rodrigues; Claire Cook; Peter G Smith; Linyan Meng; Andrew J Hall
Journal:  BMC Public Health       Date:  2004-03-03       Impact factor: 3.295

Review 8.  Anesthesia Considerations for Cataract Surgery in Patients with Schizophrenia: A Narrative Review.

Authors:  Chandra M Kumar; Howard D Palte; Alfred W Y Chua; Renu Sinha; Shreya B Shah; Farnad Imani; Zahra M Jalali
Journal:  Anesth Pain Med       Date:  2021-04-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.